Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

被引：3
|
作者：
Aguiar, Pedro, Jr. [1 ]
Perry, Luke A. [2 ]
Lopes, Gilberto L., Jr. [3 ]
机构：
[1] Univ Fed Sao Paulo, Oncol & Hematol Dept, Clin Oncol Sect, Sao Paulo, Brazil
[2] Monash Univ Sch Med, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
LUNG CANCER MANAGEMENT | 2016年 / 5卷 / 03期
关键词：
cost-effectiveness; health technology assessment; immunotherapy; lung cancer;
D O I：
10.2217/lmt-2016-0016
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：119 / 122
页数：4
相关论文
共 50 条
  • [1] Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
    Aguiar, Pedro Nazareth
    Tadokoro, Hakaru
    Barreto, Carmelia Maria Noia
    Santoro, Ilka Lopes
    De Mello, Ramon Andrade
    Babiker, Hani M.
    Avancha, Kiran
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors'
    Ogale, S.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2140 - 2140
  • [4] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [5] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [6] Reply to the letter to the editor 'Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' by Ogale
    de Lima Lopes, G.
    Aguiar, P., Jr.
    ANNALS OF ONCOLOGY, 2019, 30 (01) : 149 - 150
  • [7] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [8] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Santoro, Ilka
    Babiker, Hani
    Avancha, Kiran
    Gutierres, Barbara
    Barreto, Carmelia
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
  • [9] Immune checkpoint inhibitors' (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis.
    Maciel, Glauber
    Carlos, Paula
    Murad Junior, Munir
    Araujo, Vania Eloisa
    Guerra, Augusto
    Acurcio, Francisco Assis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC (vol 28, pg 2256, 2017)
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1078 - 1078
12345